Tracy Beth Høeg, a former resident physician and ultramarathon runner, made headlines back in 2008 for expressing her dismay at vice presidential candidate Sarah Palin’s denial of climate change. In a blog post, she criticized Palin for disregarding scientific evidence and making decisions based on belief rather than facts.
Fast forward seventeen years, and Høeg is now set to take on the role of acting director of the FDA’s Center for Drug Evaluation and Research. This position requires a thorough and unbiased review of scientific evidence regarding the benefits and risks of medical treatments. While Høeg’s colleagues and superiors believe she is qualified for the job, her tenure as the scientific adviser to FDA Commissioner Marty Makary has raised concerns about her ability to oversee drug regulation without bias.
As Høeg prepares to step into her new role, accusations have surfaced from FDA staff members regarding her alleged tendency to base decisions on belief rather than scientific evidence. This has sparked debates about her suitability for a position that demands objectivity and adherence to scientific principles.
The controversy surrounding Høeg’s appointment comes at a critical time when drug regulation is under intense scrutiny due to the ongoing pandemic and the urgent need for safe and effective treatments. The FDA plays a crucial role in ensuring the safety and efficacy of medications, and any hint of bias or lack of objectivity could have serious consequences for public health.
It remains to be seen how Høeg will navigate these challenges and fulfill her responsibilities as acting director of the FDA’s Center for Drug Evaluation and Research. As the debate rages on, the spotlight is firmly on her, as she strives to prove her critics wrong and demonstrate her commitment to upholding the highest standards of scientific integrity in drug regulation.
